Keywords: primary cutaneous lymphomas; aggressive cutaneous B cell lymphomas; rituximab; target therapy; new monoclonal antibodies Rituximab monotherapy was proven effective in primary cutaneous low-grade B cell lymphomas, whereas the ESMO clinical practice guidelines indicate immunochemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) as first-line treatment for PCDLBCL-LT ([10]). 5 Pham-Ledard, A, Prochazkova-Carlotti, M, Andrique, L, Cappellen, D, Vergier, B, Martinez, F, Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Primary cutaneous lymphomas, aggressive cutaneous B cell lymphomas, rituximab, target therapy, new monoclonal antibodies. [Extracted from the article]